Why Is VIKING THERAPEUTICS (VKTX) Stock Moving Today?
By the Top Tier Newswire AI Desk · September 23, 2026 at 10:07 AM ET · reviewed against 44 wire stories
VIKING THERAPEUTICS (VKTX) is drawing unusual attention today. Our newswire has captured 44 stories on VKTX across 24 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Viking Therapeutics (VKTX) is moving higher today amid a wave of positive news surrounding its lead obesity drug candidate, VK2735. The stock has surged following the release of top-line data from a clinical trial showing the drug can help patients maintain weight loss even with less frequent dosing. The development has drawn attention from analysts and investors, with some suggesting the drug could compete with top GLP-1 therapies such as Eli Lilly’s Zepbound.
What Happened
VKTX shares opened lower on a -1.3% gap from the previous close but quickly reversed to post gains. The stock’s movement follows the release of data from a maintenance study in obesity and type 2 diabetes, which showed that patients taking VK2735 retained a significant portion of their weight loss with once-monthly or every-other-week dosing. The drug is a dual GLP-1/GIP candidate, a class that has shown promise in the obesity treatment space. Analysts have noted that this could make it a compelling alternative to existing injectables. The news was highlighted in multiple reports, with Morningstar and The Motley Fool among the outlets covering the development. Oppenheimer raised its price target for the stock, adding to the momentum.
What The Data Shows
The stock has moved +20.7% over the last eight sessions, rising from $31.98 to $38.58. Intraday trading showed a volatile session, with the stock peaking at $42.92 before retreating to $38.19 at the close. Volume has been elevated at 3.1 million shares traded, 1.4 times the 3-month average. The stock has printed one fresh 52-week high and 11 fresh 52-week lows on September 23. Options activity has also been notable, with $9.0 million in call premiums traded and no put premiums. Three unusual options prints were recorded, the largest being $3.4 million. On the fundamentals, the company has a market cap of $3.4 billion, but it remains unprofitable with an EPS TTM of -4.67.
What To Watch
The company is set to discuss top-line data from the VK2735 maintenance study in more detail, with a presentation scheduled for September 22, 2026. Investors will also be watching for further analyst commentary and how the stock performs against peers in the GLP-1/GIP space.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
VKTX · Sep 23 session (5-min) · -6.76% vs prior close · updated 8:58 PM ETAI sentiment, last 36h · averaged over 44 stories · 66/100 bullish
The headlines behind the move
Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline
45d agoMorningstarBULLISH 67Product/PR
This GLP-1 drug helped people maintain their weight loss in a clinical trial - even for those taking it once a month
Viking Therapeutics is developing VK2735, a GLP-1/GIP drug that could compete with Eli Lilly’s Zepbound. Its stock is soaring.
45d agoThe Motley FoolBULLISH 73Product/PR
Why Viking Therapeutics Stock Skyrocketed on Tuesday
The biotech's obesity drug candidate could make it easier for people who have recently lost weight to keep it off.
45d agoStocktwits NewsBULLISH 64Product/PR
VKTX Stock On Track To Beat LLY, NVO This Month After Obesity Drug Data — Can Viking Win Over Wegovy And Zepbound Users?
Obesity specialist Lou Aronne said switching from a GLP-1 drug to a dual GLP-1/GIP drug could mean greater weight loss.
45d agoCNBCBULLISH 73Product/PR
Viking Therapeutics' shares surge on weight loss drug trial
45d agoMorningstarBULLISH 73Product/PR
Health Care Up as Viking Surges - Health Care Roundup
Viking Therapeutics shares jumped by roughly one-third after a study showed that patients taking its weight-loss injection could keep weight off even when switching to less frequent doses.
45d agoStocktwits NewsBULLISH 63General
Nasdaq Jumps To Close At Record As Chipmakers Climb, Oil Prices Cool — AAPL, META, SPCX, MSFT, VKTX In Focus
Wall Street is gearing up for this week’s summit between Donald Trump and Chinese President Xi Jinping.
45d agoStocktwits NewsBULLISH 67Analyst
VKTX Stock Jumps 36% As Oppenheimer Hikes Target, Peers Call Data A Win
The San Diego company is trying to carve out a place beside Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy with a dual GLP-1/GIP drug that can be given as a shot or, later, a pill.
45d agoSeeking AlphaBULLISH 56Product/PR
Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes Transcript
Viking Therapeutics, Inc. (VKTX) Discusses Top Line Data from VK2735 Maintenance Study in Obesity and Type 2 Diabetes September 22, 2026 8:00 AM EDTCompany...
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →